Rare copy number variation in posttraumatic stress disorder
- PMID: 36131047
- PMCID: PMC9763110
- DOI: 10.1038/s41380-022-01776-4
Rare copy number variation in posttraumatic stress disorder
Abstract
Posttraumatic stress disorder (PTSD) is a heritable (h2 = 24-71%) psychiatric illness. Copy number variation (CNV) is a form of rare genetic variation that has been implicated in the etiology of psychiatric disorders, but no large-scale investigation of CNV in PTSD has been performed. We present an association study of CNV burden and PTSD symptoms in a sample of 114,383 participants (13,036 cases and 101,347 controls) of European ancestry. CNVs were called using two calling algorithms and intersected to a consensus set. Quality control was performed to remove strong outlier samples. CNVs were examined for association with PTSD within each cohort using linear or logistic regression analysis adjusted for population structure and CNV quality metrics, then inverse variance weighted meta-analyzed across cohorts. We examined the genome-wide total span of CNVs, enrichment of CNVs within specified gene-sets, and CNVs overlapping individual genes and implicated neurodevelopmental regions. The total distance covered by deletions crossing over known neurodevelopmental CNV regions was significant (beta = 0.029, SE = 0.005, P = 6.3 × 10-8). The genome-wide neurodevelopmental CNV burden identified explains 0.034% of the variation in PTSD symptoms. The 15q11.2 BP1-BP2 microdeletion region was significantly associated with PTSD (beta = 0.0206, SE = 0.0056, P = 0.0002). No individual significant genes interrupted by CNV were identified. 22 gene pathways related to the function of the nervous system and brain were significant in pathway analysis (FDR q < 0.05), but these associations were not significant once NDD regions were removed. A larger sample size, better detection methods, and annotated resources of CNV are needed to explore this relationship further.
© 2022. The Author(s).
Conflict of interest statement
MBS has in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech and has stock options in Oxeia Biopharmaceuticals and Epivario. In the past 3 years, RCK has been a consultant for Datastat, Inc., RallyPoint Networks, Inc., Sage Pharmaceuticals, and Takeda. MU has been a consultant for System Analytic. All other authors report no biomedical financial interests or potential conflicts of interest.
Figures
References
Publication types
MeSH terms
Supplementary concepts
Grants and funding
- R01 HD102974/HD/NICHD NIH HHS/United States
- R01 AG064955/AG/NIA NIH HHS/United States
- MC_QA137853/MRC_/Medical Research Council/United Kingdom
- I01 BX004312/BX/BLRD VA/United States
- R01 MH124847/MH/NIMH NIH HHS/United States
- R01 MH091391/MH/NIMH NIH HHS/United States
- R01 MH119227/MH/NIMH NIH HHS/United States
- U01 MH119690/MH/NIMH NIH HHS/United States
- R01 AG076838/AG/NIA NIH HHS/United States
- IK6 BX006186/BX/BLRD VA/United States
- U01 MH109539/MH/NIMH NIH HHS/United States
- R01 MH129722/MH/NIMH NIH HHS/United States
- R01 AG050595/AG/NIA NIH HHS/United States
- U01 MH119739/MH/NIMH NIH HHS/United States
- I21 BX005872/BX/BLRD VA/United States
- MC_PC_17228/MRC_/Medical Research Council/United Kingdom
- R01 MH106595/MH/NIMH NIH HHS/United States
- R01 DA017846/DA/NIDA NIH HHS/United States
- K01 MH118467/MH/NIMH NIH HHS/United States
- MR/L010305/1/MRC_/Medical Research Council/United Kingdom
